We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Now only authorised for use in patients with symptomatic bone metastases and no known visceral metastases who have had 2 previous systemic treatments for metastatic castration-resistant prostate cancer or who cannot receive other systemic treatments. Do not use in combination...
Employment Tribunal decision.
Importance of establishing wildtype RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer.
Latest evidence suggests long-term use of combined oral contraceptives or progestogen-only injectable contraceptives is associated with a small increased risk of cervical cancer.
Use of pioglitazone is associated with a small increased risk of bladder cancer. Healthcare professionals should be aware of new warnings and precautions for use in at-risk patients
New data have confirmed that the risk of breast cancer is increased during use of all types of HRT, except vaginal estrogens, and have also shown that an excess risk of breast cancer persists for longer after stopping HRT than...
The first major report using world-first systemic anticancer treatment (SACT) data has been published by Lancet Oncology today (31 August 2016).
The European Medicines Agency has advised that no change in recommendations for use is required at present.
New study shows use of oral contraceptives reduces risk of ovarian cancer.
The first national study of its kind in England shows cancer patients have a 20% increased risk of suicide.
Advise patients treated with ingenol mebutate gel to be vigilant for new skin lesions and to seek medical advice immediately should any occur. Use with caution in patients with a history of skin cancer.
(All) uncertain evidence that women with breast implants may have a very small but increased risk of anaplastic large cell lymphoma (ALCL) of the breast - none reported in the UK. (MDA/2011/017)
Thousands more cancer patients in England will be offered vital treatments in a £160m boost to the Cancer Drugs Fund, Health Secretary Jeremy Hunt announced today.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Businesses can apply for a share of up to £5.4 million for projects that apply whole genome sequencing to the analysis of cancer.
The one year survival rate for teenagers and young adults diagnosed with cancer is more than 90% but the percentage of those who die within 12 months varies greatly according to cancer type.
Monitor patients for signs and symptoms of hypercalcaemia after discontinuation of denosumab treatment for giant cell tumour of bone. Cases of rebound hypercalcemia have been reported up to 9 months after cessation of treatment.
Prime Minister announces £400 million package to boost research and treatment for cancer, and a new partnership to help map genomes.
Figures reveal the stark reality of early diagnosis on survival rates
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).